News for 'CTIX' - (Cellceutix to Pursue Significant

New Post Public Reply Private Reply Replies (2) Message Board

Nov 4, 2013 at 7:15 AM

News for 'CTIX' - (Cellceutix to Pursue Significant Conjuctivitis and Kerititis Ocular Markets With Novel Antibiotic Brilacidin)

BEVERLY, MA, Nov 04, 2013 (Marketwired via COMTEX) -- Cellceutix Corporation
(OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company
developing innovative therapies in oncology, dermatology, and antibiotic
applications, is pleased to inform shareholders that the Company is conducting
experiments on Brilacidin(TM), its lead antibiotic compound, for ophthalmic
infections, including keratitis and conjunctivitis. Cellceutix estimates the
market potential for these indications well in excess of $1 billion and has its
antibiotic team expanding upon the significant amount of preclinical research
that has been conducted on Brilacidin for these conditions.

Prior to the Cellceutix acquisition of PolyMedix in September, lab studies
conducted at the Charles T. Campbell Ophthalmic Microbiology Laboratory at the
University of Pittsburgh demonstrated the safety, tolerability and broad
activity of Brilacidin against clinically important Gram-positive and
Gram-negative pathogens, including drug-sensitive and drug-resistant clinical
isolate strains of ocular infections.

Pharmacokinetic studies were conducted at Iris Pharma, a Contract Research
Organization based in France, showing that Brilacidin has a high residence time
on the surface of the eye with negligible systemic exposure. This indicates that
effective therapeutic concentrations of Brilacidin can be maintained in the eye
with infrequent treatments.

As a defensin-mimetic, Brilacidin is a completely novel class of antibiotics and
a platform for a broad spectrum of indications in an area of urgent need for new
drugs. Topical ophthalmic anti-infective drugs that are used today for keratitis
and conjunctivitis have serious limitations due to bacterial resistance and
serious side effects. For example, although exclusive of topical uses of
fluoroquinolones for eye and ear infections, the U.S. Food and Drug
Administration in August required that drug labels and Medication Guides for all
systemic fluoroquinolone antibacterial drugs be updated to describe the
potential serious side effect of peripheral neuropathy.

"The Brilacidin ocular data is highly exciting. Our new research program
focusing on ocular drugs is the next step in expanded uses of Brilacidin that we
believe will develop into a blockbuster antibiotic drug franchise," said Dr.
Krishna Menon, Chief Scientific Officer at Cellceutix. "We have a litany of
clinical and preclinical data on Brilacidin. Our research staff is currently
growing epithelial cells for testing so that we can formulate Brilacidin as a
topical solution with efficient penetration of the epithelium to maximize
clinical results."

"We are going to continue aggressively moving forward with Brilacidin as the
current biotechnology environment is desperate for new therapeutics," added Leo
Ehrlich, Chief Executive Officer at Cellceutix. "Reuters reported only yesterday
that Swiss drugmaker Roche is poised to get back into antibiotics because of a
novel drug that they want to develop to tackle drug-resistant bacteria. Simply,
a novel drug has phenomenal sales potential. Johnson & Johnson's Levaquin was
generating $1.3 billion in sales before it came off patent. Cubist's Daptomycin
for ABSSSI only comprised 8 percent of total doses, yet controlled approximately
82 percent of total sales in that market. The majority of approved antibiotics
today are legacy drugs or variations of them for which resistance is constantly
evolving. Our plan is to establish Brilacidin as the next generation antibiotic.
It has opened a door to a multi-billion-dollar pathway and we are not just
looking at it, we are part way through it and moving as quickly as possible to
establish a leadership position."

About Cellceutix:

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company
under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical
company developing innovative therapies in oncology, dermatology and antibiotic
applications. Cellceutix believes it has a world class portfolio of compounds
and is now engaged in advancing its compounds and seeking strategic
partnerships. Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1
clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth
Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce
activation of p53, often referred to as the "Guardian Angel Gene" due to its
crucial role in controlling cell mutations. Cellceutix is planning a Phase 2
clinical trial with its novel compound Brilacidin-OM for the prevention and
treatment of Oral Mucositis. Brilacidin-OM, a defensin mimetic compound has
shown in the laboratory to reduce the occurrence of severe ulcerative oral
mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug
Prurisol is being readied for a Phase 2/3 clinical trial at sites in the U.S.
and Europe. Prurisol is a small molecule that acts through immune modulation and
PRINS reduction. Cellceutix's key antibiotic, Brilacidin, is set to begin a
Phase 2b trial in the first half of 2014 for Acute Bacterial Skin and Skin
Structure Infections, or ABSSSI. Brilacidin has the potential to be a
single-dose therapy for multi-drug resistant bacteria or a dosing regimen that
is shorter than currently marketed antibiotics. Cellceutix has formed research
collaborations with world renowned research institutions in the United States
and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical
Center, and the University of Bologna. More information is available on the
Cellceutix web site at www.cellceutix.com

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995 that
involve risks, uncertainties and assumptions that could cause Cellceutix's
actual results and experience to differ materially from anticipated results and
expectations expressed in these forward looking statements. Cellceutix has in
some cases identified forward-looking statements by using words such as
"anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans,"
"intends," "goal," "potential," "may," "suggest," and similar expressions. Among
other factors that could cause actual results to differ materially from those
expressed in forward-looking statements are Cellceutix's need for, and the
availability of, substantial capital in the future to fund its operations and
research and development; including the amount and timing of the sale of shares
of common stock to Aspire Capital; the fact that Cellceutix's compounds may not
successfully complete pre-clinical or clinical testing, or be granted regulatory
approval to be sold and marketed in the United States or elsewhere. A more
complete description of these risk factors is included in Cellceutix's filings
with the Securities and Exchange Commission. You should not place undue reliance
on any forward-looking statements. Cellceutix undertakes no obligation to
release publicly the results of any revisions to any such forward-looking
statements that may be made to reflect events or circumstances after the date of
this press release or to reflect the occurrence of unanticipated events, except
as required by applicable law or regulation.

Contact:

INVESTOR AND MEDIA CONTACT:

Cellceutix Corp.

Leo Ehrlich

(978) 236-8717

Email Contact

SOURCE: Cellceutix

(C) 2013  Marketwire L.P.  All rights reserved.

-0-

SUBJECT CODE:     Pharmaceuticals and Biotech:Biotech

                  Pharmaceuticals and Biotech:Trials

                  Pharmaceuticals and Biotech:Equipment and Supplies

                  Pharmaceuticals and Biotech

rugs

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fast Renovations Could Save Homeowners Big Bucks

Speed Matters in Renovation Projects You ever been locked in that eternal waiting game with a renovation project? It's a killer for the wallet. Chapter Renovation's digging into this mess, showing how dragging out a project can cost homeowners plenty more than they bargained for. They've been pushing an average completion time of 38 weeks. Compare that to the chilling...

UN Forum Unleashes LatAm CEO Coalition for Action

Latin America Takes Center Stage When the UN turns its spotlight on a region, you know there's something afoot. Right in Montevideo, Uruguay, the United Nations Global Compact gathered a hefty crowd of over 300 leaders from diverse backgrounds—think business, finance, government, and academia. What they were brewing wasn’t just talk; it was about driving real change...

Lululemon Faces Lawsuit Over Alleged Fraudulent Reporting

What's Stirring the Pot for Lululemon? Talk about a rollercoaster. Over here, Lululemon (NASDAQ:LULU) is navigating turbulent waters, facing a class action lawsuit for alleged securities fraud. Investors who bought into the brand between March 18, 2026, and September 3, 2026, are now watching their investments drop, following what's claimed as misleading trumpet calls...

TORM's Q3 Results Point to Strength Amid Global Chaos

TORM Navigates Chaotic Waters With Impressive Earnings Alright, TORM's catching my eye here amidst what seems like a global logistical mess. These folks are proving that chaos can indeed be lucrative. Cranking out robust numbers in Q3 2026, they've managed to steer through the murky oil trade waters carved by US-Iran tensions. We're seeing TORM's time charter equivalent...

Singtel, Ericsson Push 6G Healthcare to the Forefront

Breaking Ground in Healthcare Tech Ah, what’s cooking in Singapore? On a day like today, when the tech giants Singtel and Ericsson get chummy with National University Health System (NUHS), we're looking at the kind of healthcare advancements that read like science fiction. They’ve signed an MOU to launch the National University XG AI Centre (NXAC) – a mouthful,...

Exiger Lands $12M Deal with USAF for ICBM Insights

Exiger's New Partnership: A $12M Heavyweight Move The Air Force isn’t about to let its guard down when it comes to those intercontinental ballistic missiles. Nope, the powers that be have decided it’s time to pump some serious dough into the chain that keeps those missiles ready to go, handing $12 million over to Exiger to light the path through the complex web of the...

Hyundai Pushes Hydrogen Boundaries at 2026 Expo

A Bold Step Into the Hydrogen Era Hyundai's really stepping it up at the World Hydrogen Expo 2026. They're not just dipping their toes in the hydrogen pool—they're diving in headfirst, showing off integrated hydrogen solutions that are nothing short of ambitious. Hydrogen Production That's a Real Game Changer This ain't just talk. Hyundai's showcasing modular PEM...

Smartphone Durability: What Investors Need to Know

When a Drop Becomes a Cost-Benefit Analysis As someone who’s been around the block more times than I care to count, here’s a nugget for you: we rarely think about all the little things that could drill a hole in our pockets until they do. Take smartphones, the ubiquitous little beasts we carry everywhere. An accidental drop, one moment you’re butterfingering it in...

Minghui and ASKA Seal Major Licensing Deal for MHB018A

Breaking New Ground in Thyroid Eye Disease Treatment If there's one thing that keeps the biopharma world on its toes, it's the relentless pursuit of groundbreaking treatments. And folks, let me tell you, the latest tie-up between Minghui Pharmaceutical and ASKA Pharmaceutical has struck a chord. This union with MHB018A at its core might be one of those watershed moments...

New CMO Joins ARTHEx: Boosting Innovative RNA Focus

ARTHEx Biotech's Strategic Expansion Looks like ARTHEx Biotech is shaking things up with some strategic moves by bringing in Dr. Christian Freitag as their new Chief Medical Officer. Now, if you’re knee-deep in the biotech game, you'll know that having someone like Freitag onboard is akin to adding a star player to your lineup. The guy's got more than two decades of...